Peer-influenced content. Sources you trust. No registration required. This is HCN.

FoundationOne CDx Approved as Companion Diagnostic for Capmatinib for METex14 NSCLC

The approval of capmatinib and its companion diagnostic is the first of its kind for this specific diagnosis, using next-generation sequencing to perform comprehensive genomic profiling of solid tumors. It now has FDA approval for 21 different agents.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form